NEJM: Oral Targeted Drug Sunvozertinib Outperforms Chemotherapy in Lung Cancer with EGFR exon20ins Mutation
An international Phase III study, WUKONG28, showed that the new EGFR inhibitor sunvozertinib significantly outperforms standard chemotherapy as a first-line treatment for patients with non-small cell lung cancer harboring EGFR exon20ins mutations. Results published in the New England Journal of Medicine (NEJM) demonstrate a 35% reduction in the risk of progression or death (HR=0.65) and an objective response in 58.9% of patients.
A Quiet Revolution in Oncology: Why Sunvozertinib Is Changing the Game While Big Pharma Stays Quietly Nervous
[The Core]: What’s Really Happening
I’ve been tracking the EGFR-inhibitor market for about seven years, and what just happened isn’t just another successful targeted therapy. On May 29, 2026, the New England Journal of Medicine published the WU-KONG28 results, burying several inconvenient truths that oncology’s elite had been repeating for years.
Sunvozertinib is now first-line for EGFR exon20ins, and the data are stark: PFS HR of 0.65, a 35% reduction in risk of progression or death. Median progression-free survival reached 10.3 months versus 7.5 months with chemotherapy. Objective response rate hit 58.9% versus a meager 31.1% with platinum plus pemetrexed. These numbers aren’t an “improvement”—they mark a paradigm shift. We’d grown used to exon20ins being the “bad mutation” that doesn’t respond to standard TKIs. Yet sunvozertinib is the first molecule to beat chemotherapy head-to-head.
What really matters—and what press releases omit—is that the drug received FDA approval back in July 2025 for second-line use. Still, most patients in the United States aren’t getting it.
Timeline and Context
Historically, the de-facto standard for this subgroup (roughly 10–12% of all EGFR-mutant NSCLC cases) has been amivantamab (Rybrevant) plus chemotherapy—an intravenous infusion that keeps patients in the chair for hours. Sunvozertinib is an oral tablet patients can take at home.
The FDA granted accelerated approval in August 2023 (second-line ORR ~45.9%) and full approval in July 2025. Yet manufacturing and supply-chain issues turned that approval into a paper promise. Zosia Piotrowska of Mass General has stated plainly at conferences: “The drug is unavailable, and it’s a major problem for patients.”
WU-KONG28, presented at ASCO 2026, began November 5, 2022 and enrolled patients across 15 countries (Japan excluded). Data cutoff was January 16, 2026.
A key detail: 90.2% of patients in the chemotherapy arm crossed over to sunvozertinib upon progression. Ethically correct, but it statistically erased any chance of showing an overall-survival difference (OS remains immature at 38.9% maturity). Rivals are betting OS won’t reach significance because of the crossover—and they’ll be right. Still, giving platinum-based chemo in 2026 when an oral option offers 10.3 months PFS and a better tolerability profile is clinical nonsense.
Winners and Losers
Biggest loser #1: Chemotherapy. Carboplatin plus pemetrexed is now background noise—7.5 months PFS, 31% responses, and a toxicity profile that makes patients miserable. Grade 3+ adverse events occurred in 49.3% of the chemo arm versus 61.3% with sunvozertinib, but the nature of those events differs sharply. Rash and diarrhea from a TKI are unpleasant; neutropenic fever and crushing fatigue from chemo destroy quality of life.
Biggest loser #2: Amivantamab (Janssen). This intravenous monoclonal antibody has PAPILLON data, yet sunvozertinib’s oral route and superior PFS (10.3 vs 7.5 months versus chemo alone) make infusion logistics a nightmare for cancer centers.
Biggest loser #3: Chinese competitors (Zipalertinib, Furmonertinib). Both are racing into first-line. Zipalertinib is betting on chemo combinations (REZILIENT3), a risky move after the EXCLAIM-2 failure with mobocertinib. Furmonertinib (FURVENT) is monotherapy. Sunvozertinib has already beaten them to NEJM publication.
Clear winner: Dizal Pharmaceuticals—and, above all, patients, provided the drug finally reaches pharmacy shelves.
What the Media Isn’t Saying
First blind spot: brain metastases. HR for patients with brain metastases (BM) on sunvozertinib was 0.96—essentially no benefit over chemo. Chemotherapy barely crosses the blood-brain barrier, so 0.96 signals that sunvozertinib may also penetrate the BBB poorly. Most reviews ignore this gap.
Second blind spot: toxicity. Grade 3+ events reached 61.3% with sunvozertinib. The chemo arm was capped at six cycles followed by pemetrexed maintenance, while patients stay on sunvozertinib indefinitely. Notably, 20.2% experienced severe CPK elevation (muscle pain, myopathy risk), 13.5% had severe diarrhea, and 7.4% discontinued treatment due to side effects.
Third: the money trail. The U.S. EGFR NSCLC market is valued at roughly $10 billion with 8% CAGR. Annual therapy could list at $400,000. Payers are already modeling real-world costs of managing severe diarrhea and CPK elevations.
Outlook: Next 30 and 90 Days
Next 30 days (June 2026): Battle for NCCN update.
The NCCN committee will almost certainly vote to include sunvozertinib in first-line exon20ins recommendations. The question is Category 1 or 2A? Given the brain-metastasis signal, a restriction to “patients without active CNS metastases” is likely—immediately trimming 20–30% of the addressable population.
The EMA is under pressure; availability in Europe is even worse than in the U.S. Expect an emergency data request on the BM subgroup within 30 days. Failure to respond quickly could delay approval another 6–9 months.
Next 90 days (August–September 2026): Payer scrutiny and manufacturing reality.
Payers (UnitedHealthcare, CVS Caremark, etc.) will run their own meta-analyses. PFS2 of 21.7 months versus 15.5 months is a powerful argument: higher upfront cost may be offset by fewer subsequent lines of therapy.
Sunvozertinib is expected to receive a positive ICER verdict—conditional on a 20–25% discount from Dizal.
The lingering wildcard remains manufacturing. The active pharmaceutical ingredient crystallizes in two polymorphic forms, one with poor bioavailability. Dizal has yet to lock in a stable commercial process. Within 90 days we’ll either see credible “capacity expansion” news or a quiet withdrawal of the EMA filing. I’m betting on the former—competitors are breathing down their necks. The upward move has already begun.
— Editorial Team
